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Summary It has been suggested that tumour development and immunocompetence are affected by the
menstrual and the oestrous cycle, and sex hormones have been shown to modulate lymphokine production,
neuroendocrine activity and immunity. In this study, we assessed natural killer cell activity and host
susceptibility to metastasis during the oestrous cycle in the Fischer 344 inbred rat strain. Females were
inoculated intravenously with MADB106 tumour cells, a syngeneic mammary adenocarcinoma cell line that
metastasises only to the lungs. The susceptibility to metastatic development of this tumour was found to be
significantly higher during pro-oestrus and oestrus than during metoestrus and dioestrus. Two days of exposure
to oestradiol benzoate caused similar effects in ovariectomised females, and a single administration of
progesterone reduced this effect of oestradiol to a statistically non-significant level. The tumour was found to
be negative for oestradiol receptors, and its in vitro proliferation rate was not affected by oestradiol or
progesterone, suggesting that the effects of sex hormones on the metastatic process are not attributable to a
direct effect on tumour cells. Because the metastatic process of MADB106 tumour cells is known, and
confirmed here, to be highly controlled by large granular lymphocyte/natural killer (LGL/NK) cell activity, we
assessed their role in mediating the effects of the oestrous cycle. The number and activity levels of circulating
blood LG/NK cells (NKR-Pl+bright) were studied. Findings indicated oestrous-dependent alterations in the
number of LGL/NK cells and suggested a diminished NK activity per LGL/NK cell during pro-oestrus/
oestrus, the same phases that were characterised by higher susceptibility to metastatic development. These
findings provide the first empirical evidence for a causal relationship between a short-term exposure to elevated
oestradiol/low progesterone levels and decreased resistance to tumour metastasis, and it is hypothesised that an
alteration in LGL/NK cell activity underlies these effects. Homologies and relevance to clinical phenomena are
discussed.
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The rate of tumour development has been associated with
phases of the oestrous/menstrual cycle and with levels of sex
hormones. In the mouse, spontaneous metastasis of an
oestrogen-responsive tumour was reduced around ovulation
(Ratajczak et al., 1988), and prolonged exposure to ,B-
oestradiol (more than 8 weeks) increased experimental and
spontaneous tumour metastasis (Hanna and Schneider, 1982).
In humans, some studies, but not others, have associated
certain periods of the menstrual cycle with a better long-term
survival rate following a breast cancer resection (Badwe et al.,
1991; Hrushesky, 1989; Saad et al., 1994; Senie et al., 1991;
Spratt et al., 1993; Veronesi et al., 1994; for review see
Davidson and Abeloff, 1993). For example, studies by Badwe
et al. (1991) and Senie et al. (1991) reported a 3-fold increase
in cancer reoccurrence and mortality in patients undergoing
surgery during the unopposed oestrogen synthesis phase
(elevated oestradiol/low progesterone levels, days 3-12 after
the last menstrual period), relative to patients undergoing
surgery during the rest of the menstrual cycle (approximately
45% vs 15% mortality rate respectively).
The effects of sex hormones on the development of
malignancies can result from direct interaction with the
neoplastic tissue (commonly via receptor systems for sex
hormones) or can be mediated indirectly via various
physiological mechanisms that affect tumour development
(e.g. levels and affinity of intercellular adhesion molecules,
vascular permeability and immune functions). The above-
mentioned clinical phenomenon is reported to occur whether
or not the excised breast tumours possess receptors for sex
hormones (Badwe et al., 1991; Saad et al., 1994; Senie et al.,
1991). Thus, it is likely that this phenomenon reflects an
indirect effect of sex hormones on tumour development.
Immune functions that control neoplasia, such as natural
killer cell, macrophage and cytotoxic T cell activities, are
potential mechanisms, and human and animal studies
demonstrated oestrous/menstrual cycle-related alterations in
cellular and humoral immunity (Sulke et al., 1985; White et
al., 1982; Gruber et al., 1988; Rager et al., 1994). Sex
hormones may directly impact anti-tumour activity of
immune effector cells or may alter levels of immune
modulators (interleukins, interferons and various hor-
mones). Indeed, alterations in monocyte and macrophage
release of interleukin (IL)-1, IL-2 and prostaglandins were
reported during the oestros/menstrual cycle and in response
to in vivo and in vitro application of sex hormones (Lynch et
al., 1994; Polan et al., 1988, 1989, 1990, 1994; Simon et al.,
1993).
Natural killer (NK) cells are known to recognise and kill
virally infected cells and tumour cells spontaneously
(Herberman and Ortaldo, 1981; Oldham, 1990) and have
been shown to control metastatic growth of several types of
tumour (Barlozzari et al., 1983; Gorelik et al., 1982; Hanna et
al., 1985; Wiltrout et al., 1985; Schantz et al., 1987; Levy et
al., 1987; Barlozzari et al., 1985; Ben-Eliyahu and Page,
1992). Few studies have reported fluctuation in NK-cell
activity during the oestrous/menstrual cycle. In female mice,
splenic NK activity was elevated around ovulation (Gruber et
al., 1988; Hrushesky et al., 1988). In women, two studies have
reported alterations in blood NK cytotoxicity during the
menstrual cycle, although findings from these studies were
not consistent (Sulke et al., 1985; White et al., 1982). None of
the above-mentioned studies assessed the number of large
granular lymphocyte (LGL)/NK cells within the population
of splenocytes/monocytes tested for NK activity. Therefore, it
is not clear whether changes in the number of LGL/NK cells
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or in the activity per cell account for the reported differences
during the oestrous/menstrual cycle. To our knowledge, no
consistent short-term in vivo or in vitro effects of oestradiol,
progesterone or testosterone on NK activity have been
reported. One study reported a lack of in vitro effects of
these hormones on a cloned human NK cell line (Callewaert
et al., 1991), and another study, using oestradiol and
tamoxifen in rats, indicated dose-dependent alterations in
NK cytotoxicity (Baral et al., 1991).
In the current study, we assessed the effects of the oestrous
cycle and sex hormones on the number and activity levels of
blood NK cells measured in vitro, and on the in vivo
resistance to metastatic development of a mammary
adenocarcinoma cell line, MADB106. This tumour line,
syngeneic to the inbred F344 rats used in this study,
metastasises only to the lungs following intravenous
inoculation, and thus constitutes a convenient model of
breast cancer metastasis. The use of this tumour simulates a
partial but well-defined subprocess of the overall metastatic
process (Barlozzari et al., 1985; Ben-Eliyahu et al., 1991; Ben-
Eliyahu and Page, 1992). There are three major advantages in
employing the MADB106 tumour model in the current study:
(1) The time interval that is most critical for the establish-
ment of metastasis is shorter than 24 h (Barlozzari et al.,
1985); therefore, the efficiency of the host anti-metastatic
activity can be correlated with the similarly short oestrous
cycle phases in the rat. (2) Host control of the metastatic
process (number of metastases established rather than size) is
markedly dependent on the activity levels of LGL/NK cells
during the first 24 h after tumour injection (Barlozzari et al.,
1985; Ben-Eliyahu et al., 1991; Ben-Eliyahu and Page, 1992).
Therefore, the resistance to metastatic development also
reflects in vivo levels of LGL/NK cell activity and suggests
the biological significance of alterations in NK activity that
we directly measure in vitro. (3) As will be reported here, the
MADB106 tumour does not express oestrogen receptors and
its in vitro proliferation rate appears not to be affected by
oestradiol or progesterone. Therefore, the use of this tumour
advances the study of the indirect effects of sex hormones on
tumour development (mediated via alteration in immunity or
other physiological mechanisms).
In order to maximise the overlap between the time of the
highest levels of sex hormones and the NK-sensitive period of
the MADB106 tumour, we chose to inoculate the rats with
tumour cells at the beginning of the light phase, when there is
a sharp rise in the levels of most sex hormones on pro-
oestrus, and to assess the cumulative anti-metastatic activity
of the host during the first 9 h after tumour inoculation. This
assessment was conducted by measuring the percentage of
tumour cells retained in the lungs 9 h after inoculation. We
and others have reported high correlation between lung
tumour cell retention within hours after tumour cell
inoculation and the consequent number of lung metastases
found 3 weeks later (Barlozzari et al., 1985; Ben-Eliyahu and
Page, 1992). Also, in various studies using this tumour model
and assessing the effects of surgery, stress, morphine or
ethanol on lung tumour cell retention and on the number of
lung metastases detected 3 weeks later, very similar effects in
these two indices were observed, and changes in NK activity
paralleled changes in susceptibility to the MADB106
metastasis (Ben-Eliyahu et al., 1991, 1993, 1996; Page et al.,
1993, 1994; 1995; Yirmiya et al., 1991, 1992).
Materials and methods
Animals, oestrous cyclicity and hormonal pattern
Fischer 344 (F344) rats were purchased from Harlan Sprague
Dawley (HSD), Indianapolis, USA, housed five per cage with
free access to food and water and kept under a 12: 12 h
light-dark cycle. Before all experiments, rats were acclima-
tised to the vivarium for a minimum of 4 weeks. The female
rat has a 4-5 day oestrous cycle consisting of the following
phases/days: pro-oestrus (pe), oestrus (e), metoestrus (me),
dioestrus day 1 (del), and a variably occurring dioestrus day
2 (de2). Oestradiol and prolactin levels, unlike those of
progesterone and other sex hormones, begin to increase
gradually during dioestrus (Lapolt et al., 1986; Nequin et al.,
1979). Levels of most sex hormones, including oestradiol,
progesterone, prolactin, LH and follicle-stimulating hormone
(FSH), rise sharply and peak during the light phase of pro-
oestrus and return to baseline levels before the oestrous day
(Lapolt et al., 1986; Nequin et al., 1979).
Ovariectomy
Females were ovariectomised at 12 weeks of age under
halothane anaesthesia through a midline abdominal incision
(for procedure see D'Amour and Blood, 1954). Sutures were
removed 10 days after surgery. Rats were allowed a minimum
of 3 weeks for recovery.
MADB106 tumour cells
MADB106 is a selected variant cell line obtained from a
pulmonary metastasis of a mammary adenocarcinoma
(MADB100) chemically induced in the inbred F344 rat
(Barlozzari et al., 1985). MADB106 cells were maintained in
5% carbon dioxide at 37°C in monolayer cultures in complete
medium [RPMI-1640 medium (Gibco, Grand Island, NY,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 45 U penicillin G ml-', 0.045 mg streptomy-
cin ml-', 2 mM L-glutamine, 0.1 mM non-essential amino
acid and 1 mM sodium pyruvate] and separated from the
flask (Falcon 3023) using 0.25% trypsin.
Radiolabelling of tumour cells and lung clearance assessment
For lung clearance assessment, DNA radiolabelling of
tumour cells was accomplished by adding 0.4 ,uCi of
['251]iododeoxyuridine ([1251]IDUR) (ICN Radiomedicals,
Irvine, CA, USA) per ml of complete media to the growing
cell culture 1 day before harvesting the cells for injection.
For tumour cell injection, rats were lightly anaesthetised
with halothane and 4x 105 kg-' ['251]IDUR-labelled
MADB106 tumour cells were injected into the tail vein in
approximately 0.5 ml phosphate-buffered saline (PBS). This
procedure requires 1-2 min, after which rats quickly awake
and behave normally. Nine hours later, rats were euthanised
with halothane and their lungs removed to measure radio-
active content in a gamma counter. Percentage radioactivity
retained in the lungs is the ratio between radioactivity
measured in the lungs and total radioactivity in the injected
tumour cell suspension. Our previous studies with radiola-
belled MADB106 tumour cells indicated that the level of
radioactivity released from intact cells is negligible (Ben-
Eliyahu and Page, 1992).
Selective in vivo depletion of LGL/NK cells
Two days before tumour inoculation or blood sampling,
1.5 mg kg-' MAb 3.2.3 (Pittsburgh Cancer Institute) was
injected intravenously (i.v.) under light halothane anaesthesia.
In vivo treatment of rats with MAb 3.2.3 selectively depletes
LGL/NK cells and eliminates NK- and antibody-dependent
non-MHC-restricted cell cytotoxicity without affecting other
immune functions; T-cell function and percentage of T cells,
monocytes and polymorphonuclear (PMN) cells are unaf-
fected (Chambers et al., 1989, 1992; van den Brink et al.,
1990). In a previous study, using this dose of the MAb 3.2.3,
we showed a complete abolition of blood and splenic LGL/
NK cytotoxicity and a 100-fold increase in the lung retention
and metastatic colonisation of MADB106 tumour cells (Ben-
Eliyahu and Page, 1992). We have also used other monoclonal
antibodies (R73, W3/25 and ED2), mouse serum and saline as
controls for the administration of the depleting agent and
found no differences between the effects of these controls and
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Whole blood NK cytotoxicity assay
Rats were lightly anaesthetised with halothane, and blood
was drawn into a heparinised syringe (20 units ml-' blood,
preservative free) by cardiac puncture. Exactly 1 ml of blood
was washed once with PBS (4 x blood volume) and twice
with complete media (3 x blood volume, 15% FBS). For
each wash, the mixture was centrifuged at 400 g for 10 min
and the supernatant removed down to the original blood
volume. For each of the six effector- target (E: T) ratios
used, 100 [u of washed blood was placed into a well of a
microtitre plate and 150 pl of 5'Cr-labelled YAC-1 tumour
cells in complete medium was then added on top of the
blood. A concentration of 8 x 105 YAC-l ml-' was used for
the lowest E:T ratio (approximately 8: 1, leucocytes: YAC-
1, depending on leucocyte concentration per ml of blood)
and sequentially divided by two for higher E: T ratios
(approximately 256: 1 at the highest). Plates were centrifuged
at 500 g for 10 min to create a buffy coat layer of leucocytes
and target cells above the red blood cells before a 4 h
incubation period. Following incubation, plates were
centrifuged again and aliquots of 100 pl of the supernatant
were recovered from each well for assessment of radio-
activity in a gamma counter. The spontaneous and
maximum release of radioactivity from tumour cells were
measured separately for each of the six tumour concentra-
tions, and percentage specific lysis was calculated for
each E: T ratio using the standard formula: [(experi-
mental release - spontaneous release)/(maximum release -
spontaneous release)] x 100.
Flowt cytometry
An aliquot of 100 ,ul of blood was combined with 50 pl of
PBS (supplemented with 2% FBS and 0.1% sodium nitrite
and 2 pg of the MAb 3.2.3 conjugated with fluorescein
isothiocyanate (Pittsburgh Cancer Institute). Samples were
kept in the dark at room temperature and incubated for
15 min before 2 ml of FACs lysis solution (Becton
Dickinson) was added. Ten minutes later, samples were
centrifuged for 5 min at 500 g and the lysis solution
aspirated. Cells were washed again with 2 ml of PBS (5 min
centrifugation, 500 g) and resuspended in 300 pl of PBS for
flow cytometry analysis using a FACScan (Becton Dick-
inson). The MAb 3.2.3 has been shown in the rat to recognise
a surface antigen, NKR-P1, which is expressed exclusively on
fresh and IL-2-activated LGL/NK cells (MAb 3.2.3+bright)
and, to a much smaller degree, on polymorphonuclear
(PMN) cells (MAb 3.2.3+dim) (Chambers et al., 1992). Our
experience with this procedure has indicated that there is no
overlap between the bright and the dim cells (Ben-Eliyahu et
al., 1993). The number of white blood cells per ml of blood
was assessed in each blood sample using a Coulter counter.
Counterbalancing, timing ofprocedures and statistics
The time and order of blood draw, drug administration and
tumour injection were counterbalanced across groups and
oestrous phases in all experiments. For each experiment, the
procedure of either tumour inoculation or blood draw was
completed within less than 2 h in all animals and was
conducted during the first half of the light phase (unless
otherwise noted). One factor ANOVA was conducted
(repeated measures for NK cytotoxicity in experiment 4).
Bonferroni post hoc tests or planned contrasts were used to
identify specific differences. An alpha of 0.05 was set for all
experiments.
Experiment 1. The effects of the oestrous cycle on host
resistance to metastasis and LGL/NK sensitivity of the
metastatic process
Oestrous cyclicity and phase were determined according to
the method described in Everett (1989) based upon vaginal
cellularity. Daily vaginal smears were performed in 6-month-
old females (200 g, n= 34 cycling females) for 9 consecutive
days during the first half of the light phase. On the tenth
day, at the same time of vaginal cellularity sampling, each
rat was inoculated with MADB106 tumour cells. To
compare males with females, and to establish a relationship
between the dose of tumour injected and the percentage of
tumour cell retention, similarly handled age-matched males
(350 g) were injected with either the same dose, one-half or
twice the dose of tumour cells per body weight (n= 6, 5 and
5 respectively). Tumour cell retention was assessed in all rats
at 9 h after tumour injection. In a replicate study, 18 cycling
females were used as described above. Six were selectively
depleted of LGL/NK cells before tumour injection to verify
the dependence of lung clearance on LGL/NK cells in this
paradigm.
Experiment 2: The effects of oestradiol and progesterone on
host resistance to metastasis in ovariectomised females
Ovariectomised (OVX) females were injected subcutaneously
(s.c.) with oestradiol benzoate (EB) or progesterone (P) at
different time intervals before tumour inoculation, and lung
tumour retention was measured. Ovariectomised females
(210 g, 15 weeks old, n=57) were randomly assigned to the
following groups and were given five successive daily
injections of drugs/vehicle (Figure 2). One group received
vehicle injections throughout the 5 day period (control); two
groups received drugs only on the fifth day, one group
receiving P (6 mg kg-' in 0.25 ml of peanut oil), and the
second group 16 ,ug kg-' EB (in 0.25 ml of corn oil); three
groups were also injected with an overall dose of 16 ,ug kg-'
EB that was given in two successive injections (8 jug kg-'
each), one group on days 1 and 2, the second group on days
4 and 5, and the third group also on days 4 and 5, but
concomitantly with P (6 mg kg-') on day 5. On the sixth
day, all rats were inoculated with radiolabelled MADB106
cells and euthanised with halothane 9 h later to assess lung
tumour retention.
The doses of EB were chosen to induce high physiological
levels of oestradiol for approximately 24-48 h after
administration. In the intact female rat, average serum
oestradiol levels increase from 15 pg ml-' on oestrous/
metoestrous days to 55 pg ml-' on pro-oestrus day (Lapolt
et al., 1986). The 15 pg ml-' level found on metoestrous day
was elevated to 25 pg ml-' within 12 h after the administra-
tion of 4 ,ug kg-' EB, or elevated to 160 pg ml-' after the
administration of 80 pg ml-' EB. These elevated levels
decreased and approached baseline levels within 24 and
48 h respectively in OVX rats (Matt et al., 1986). Based on
these reports and approximated linear relationships between
levels of EB injected and induced blood levels of oestradiol,
we injected a total of 16 pg kg-' EB to OVX females,
estimating the induced oestradiol levels to be approximately
40 pg ml-'. The dose of progesterone used is the standard for
the induction of proceptivity in OVX females (following
sensitisation with oestradiol). EB and progesterone were
dissolved in the specific oil vehicle indicated in the literature
reporting their serum levels.
Experiment 3. In vitro effects of oestradiol and progesterone
on MADB106 tumour proliferation, and the levels of oestradiol
and progesterone receptors on MADB106
Oestradiol or progesterone at concentration of 10-8, 10-9,
10-"' and 10`" M or vehicle were added to the growing
culture of MADB106 cells, and cells were harvested and
counted at 24 or 48 h after addition of these hormones. In a
separate experiment, MADB106 tumour cells were tested for
oestradiol and progesterone receptors using the standard
clinical procedure described in Geier et al. (1982), and the
MCF-7 tumour line was tested for progesterone receptors as
a positive control.Oestrous effects on metastasis and NK activity
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Experiment 4: Oestrous cycle and the number and activity level
of circulating LGL/NK cells
Flow cytometry was used to assess the number of blood
LGL/NK cells (MAb 3.2.3-bright) per ml of blood, and the
whole blood NK cytotoxicity assay was used specifically to
assess LGL/NK cytotoxicity per ml of blood. Three different
assessments of whole blood NK cytotoxicity were conducted
(n=70, 65 and 34; age= 12, 16 and 20 weeks; bw =200-
220 g). Blood was taken during the first half of either the
dark phase (first study) or the light phase (second and third
studies). To verify that the whole blood cytotoxicity assay
specifically assesses LGL/NK cell-dependent cytotoxicity, rats
selectively depleted of LGL/NK cells were also used in these
experiments. Flow cytometry was conducted twice during the
light phase, once using 20-week-old females (n= 34,
bw=220 g) and once using 10-week-old females (n=9,
bw=210 g). Each assessment was conducted using cycling
females that underwent daily vaginal cellularity sampling for
the 9 days before blood withdrawal for either NK activity or
flow cytometry.
Results
Experiment 1
The oestrous cycle and its effects on host resistance to
metastasis Significant differences in tumour cell retention
across the 5 oestrous days were evident (F(4,29) 4.76,
P<0.01) (Figure 1). Specifically, rats in pro-oestrus and
oestrus showed a higher percentage of tumour cell retention
than rats in metoestrus and dioestrus (P<0.05, Bonferroni
post hoc test). The three groups of males injected with an
increasing tumour load showed an increasing percentage of
tumour cell retention (F(2,13)=4.3, P<0.05). Compared with
the females, males injected with an equal number of tumour
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cells per body weight retained a lower percentage of tumour
cells than females in pro-oestrus/oestrus [i.e. demonstrated a
better lung clearance efficiency, (F(534)=5.7, P< 0.05, planned
contrast], but similar levels of retention compared with
females in metoestrus/dioestrus. The males injected with
twice the dose of tumour cells per kg relative to females
exhibited tumour cell retention midway between the low and
high levels observed in females during metoestrus/dioestrus
and pro-oestrus/oestrus respectively.
In the replicate study, similar oestrous effects were evident
in normal cycling females (pro-oestrus/oestrus=0.56% radio-
activity retained, s.e.m. =0.061; metoestrus/dioestrus=0.40%,
s.e.m. =0.025; t,( 5.5, P<0.05). Oestrous phases were
collapsed to pro-oestrus/oestrus vs metoestrus/dioestrus
based on the findings from the first study and because of
the small number of animals.
Oestrous cycles did not synchronise within or between
cages in any of the studies conducted. More than 90% of
females had regular 4-5 day cycles, the great majority of
which had a 5 day oestrous cycle.
The eftects of selective depletion of LGLINK cells on lung
tumour retention Selective depletion of LGL/NK cells
resulted in approximately a 100-fold increase in tumour cell
retention from 0.48% (s.e.m. =0.045) in normal rats to 38%
in the six depleted animals (ranging from 24% to 54%). The
relationship between oestrous phase and tumour retention in
this small group of LGL/NK-depleted animals was not tested
for methodological reasons. The purpose of the depletion was
merely to verify the LGL/NK sensitivity of the tumour.
Experiment 2
The effects ofoestradiol andprogesterone on host resistance to
metastasis in OVX ftnmales The results showed that,
compared with vehicle-injected rats, OVX rats receiving
16 pg kg-' EB given in two equal injections on the last 2
days, but not in one injection on the last day before tumour
injection, exhibited a significant increase in tumour cell
retention (F()551) =2.6, P<0.05, Bonferroni post hoc test)
(Figure 2). No such increase was evident in the groups that
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Figure 1 The percentage of tumour cell retention in males
following injections of three different tumour loads, and in
females in proestrus (pe), oestrus (e), metoestrus (me), dioestrus 1
(del) and dioestrus 2 (de2). Compared with females (-* ),
males were injected with either an equal number of tumour cells
per kg ( 0 ), half as many (- - -0- - - half tumour load) or
twice as many (- - -0- - - double tumour load). Females in pro-
oestrus/oestrus showed a significantly higher percentage of
tumour cell retention than females in metoestrus/dioestrus. In
males, the increasing tumour load resulted in a significant increase
in tumour retention. Males injected with females' load of tumour
cells per bw (males) retained a significantly lower percentage of
tumour cells than females in proestrus/oestrus, but did not differ
from females in metoestrus/dioestrus. In females, vertical bars
represent s.e.m.; pe day is shown twice. Variance in the three male
groups was similar to that observed in the five female groups
(std=approximately 0.07%).
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Figure 2 The effects of oestradiol and progresterone on lung
tumour cell retention in ovariectomised females. All rats were
given five successive daily injections of drugs/vehicle and were
inoculated with the tumour on the sixth day. Control rats (Cont)
received vehicle injections only. In the five experimental groups,
only drug injections are indicated in the figure and the day of
each injection is specified by a subscript index. Each injection
contained one of the following: progesterone (P), oestradiol
benzoate (E), oestradiol benzoate and progesterone (EP) or a
double dose of oestradiol benzoate (2E). Vertical bars represent
s.e.m. *Significantly different from the control group (P<0.05).OM Oestrous effects on metastasis and NK activity
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received the same 2 day treatment with EB either 4 days
before tumour injection or 2 days before tumour injection
together with progesterone on day 5.
Experiment 3
In vitro effects of oestradiol and progesterone on MADB106
tumour proliferation Enumerating MADB106 tumour cells
following 1 or 2 days of incubation indicated that the cells
divided approximately every 18 h, and this rate was not
affected by oestradiol or progesterone in the concentrations
used.
Oestradiol and progesterone receptors on MADB106 The
MADB106 tumour was found to be negative for oestradiol
receptors (undetectable levels) and expressed low levels of
progesterone receptors (19.4+2.1 fmol mg-'), which were
significantly lower than in the MCF-7 tumour line
(51.6+4.6 fmol mg-' (t8=6.3, P<0.05).
Experiment 4
Oestrous cycle and LGL/NK cell number and activity
levels Females in pro-oestrus and oestrus exhibited a
significantly greater number of LGL/NK cells (MAb
3.2.3+bright) per ml of blood compared with animals in
metoestrus/dioestrus, in each of the two replicate assessments
(Table I includes averages and statistics). Despite this
difference in LGL/NK number per ml of blood, there were
no significant oestrous phase-related differences in NK
activity per ml of blood in any of the three replications
conducted. In fact, very similar levels were observed in each
replication (Figure 3 illustrates one replication), suggesting a
lower NK activity per LGL/NK cell during pro-oestrus and
oestrus.
The blood from animals that were selectively depleted of
LGL/NK cells showed no MAb 3.2.3+ bright cells and no
cytotoxic activity. The number of LGL/NK cells per ml of
blood across the two oestrous phases was higher in 10-week-
old females than in 20-week-old females (Table I) (F(I,39)= 5.4,
P<0.05).
Discussion
The statistically significant relationship between the oestrous
cycle and lung clearance observed in this study indicates a
decrease in host resistance to metastasis during pro-oestrus
and oestrus. To provide a measure of the biological
significance of the differences in lung tumour retention
among oestrous phases, it is noteworthy that a difference of
similar magnitude was observed between the two groups of
males injected with the lowest and the highest tumour load
(i.e. a 4-fold increase in tumour load), (see Figure 1). Thus, it
might be suggested that during metoestrus/dioestrus the host
can resist four times as many tumour cells with the same rate
of success as during pro-oestrus/oestrus. Furthermore,
although the absolute differences in tumour cell retention
between the oestrous phases are not large, the relatively low
number of animals (n =4-6 per group) needed to demon-
strate significant differences (in both replications) testifies to
the robust nature of the phenomenon.
The effects of oestradiol benzoate (EB) and progesterone
on lung tumour retention in the OVX females and the time
course of these effects suggest that: (1) oestradiol adminis-
tration can simulate the increase in tumour cell retention
during pro-oestrus/oestrus observed in Experiment 1; (2)
more than 24 h of exposure to oestradiol is needed before its
full tumour-enhancing effect is evident, and this effect
dissipates within less than 3 days following discontinuation
of oestradiol treatment; and (3) progesterone, at the dose and
timing administered, appears to attenuate the effects of
oestradiol on tumour cell retention. This last suggestion is
based upon the finding that progesterone administration to
the EB-treated rats decreased the tumour-enhancing effects of
EB by approximately 50% from a significant to a non-
significant level.
In normal cycling rats, oestradiol levels begin to increase
during dioestrus, 24-48 h before pro-oestrus (Lapolt et al.,
1986; Nequin et al., 1979). Taken together, the findings in
OVX and in normally cycling females, suggest that the
gradual increase in oestradiol levels during the 2 dioestrous
days, coupled with the surge of oestradiol during pro-oestrus,
underlie the effects of the oestrous cycle on the resistance to
tumour metastasis observed in Experiment 1. The termina-
tion of this effect may be initiated by the sharp increase in
progesterone levels on pro-oestrus or may occur sponta-
neously within a day after the drop in oestradiol secretion.
Nevertheless, the administration of EB or progesterone to
OVX females is an imperfect simulation of the hormonal
milieu of the normal cycling rat. Further studies using
selective oestradiol antagonists in normal cycling rats are
needed to provide additional support for this hypothesis.
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Figure 3 Mean percentage specific killing on the different days of
the oestrous cycle (±s.em.). Cytotoxicity against different
numbers of YAC-1 target cells was assessed per 0.1 ml of
blood. No significant differences in cytotoxicity among oestrous
days were found in this replicate or in the other two replicates
conducted. Taken together with the significant alteration in the
number of LGL/NK cells per ml of blood during the oestrous
cycle (Table I), these findings indicate a suppressed LGL/NK cell
activity per LGL/NK cell during the pro-oestrous/oestrous phase.
Table I Means (+s.e.m) of LGL/NK cells per ml of blood (x 104) on different days of the oestrous
cycle in two replicate studies
pe e me del de2
Replicate 1 n=34 27.7 22.3 16.8 17.1 20.0 F(4,29)=2.81
(20-week-old rats) (1.02) (1.70) (1.71) (1.69) (2.30) P<0.05
Replicate 2 n=9 42.1 28.3 F(1,7)=10.2
(10-week-old rats) (3.68) (2.55) P<0.05Oestrous effects on metastasis and NK activity
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Several findings suggest that the in vivo effects of the
oestrous cycle and its simulation by oestradiol administration
in OVX females are not mediated via a direct effect of sex
hormones on MADB106 tumour cells. Firstly, MADBI06
cells were found to be negative for oestradiol receptors, and
their proliferation rate in vitro was not affected by oestradiol
or progesterone. Secondly, whereas 2 days, but not I day, of
oestradiol treatment in OVX females were needed to induce
its effects on MADB106 tumour retention, tumour cells were
exposed to oestradiol for an equal duration in both cases (i.e.
for 9 h beginning from tumour inoculation to sacrificing the
animal). Thus, the impact of oestradiol on the animal rather
than on the MADB106 tumour cells appears to determine
host susceptibility to metastasis of this tumour. Therefore, it
seems more likely that the effects of oestradiol or the oestrous
cycle are mediated via some alteration in the physiological
milieu that affects metastatic development.
To support the suggestion that LGL/NK cells mediate the
effects of the oestrous cycle on MADBl06 tumour metastasis
observed in this study, it is important to establish the role of
LGL/NK cells in controlling this metastatic process, and the
ability of the lung clearance assay (measured by lung tumour
retention) to reflect the effects of the oestrous cycle. In this
study, the 100-fold increase in lung tumour cell retention in
rats selectively depleted of LGL/NK cells verifies the high
sensitivity of the lung clearance assay for LGL/NK cell
activity. We and others have also used other approaches to
implicate LGL/NK cells in controlling lung tumour retention
and the consequent metastatic colonisation of the MADB106
tumour (e.g. adoptive transfer of purified LGL cells and
stimulation of LGL/NK cells), and have determined that the
NK-sensitive period of this process is shorter than 1 day
(Barlozzari et al., 1985; Ben-Eliyahu and Page, 1992). As
reviewed in the Introduction, the short-term assessment of
lung clearance is highly predictive of the actual number of
lung metastases that will grow weeks later and correlates well
with levels of NK cell activity in experimental conditions
(Barlozzari et al., 1985; Ben-Eliyahu and Page, 1992; Ben-
Eliyahu et al., 1991, 1993, 1996; Page et al., 1993, 1994, 1995;
Yirmiya et al., 1991, 1992). Thus, the lung clearance assay
constitutes a short-term index of the metastatic process and
maximises the overlap between the LGL/NK-sensitive period
of the MADB106 metastatic process and the similarly short
oestrous phases in the rat. Therefore, it could be suggested
that the decrease in lung clearance observed during pro-
oestrus/oestrus reflects a decrease in LGL/NK cell activity
during this period of the oestrous cycle. Nevertheless, because
other physiological mechanisms may, additionally or exclu-
sively, mediate the effects of the oestrous cycle or oestradiol
administration on tumour retention, more support and more
direct evidence for the involvement of LGL/NK cells is
needed.
To this end, we have directly assessed blood NK cell
number and activity in vitro. Our findings indicated a
significantly greater number of LGL/NK cells per ml of
blood during pro-oestrus and oestrus in both replications, but
no increase in LGL/NK cytotoxicity per ml of blood during
these days in any of the three replications conducted. Taken
together, these findings suggest that there is a decrease in
blood NK activity per LGL/NK cell during pro-oestrus and
oestrus. Although the blood seems to be an important
immune compartment with respect to host anti-tumour NK
activity in this tumour model (Ben-Eliyahu and Page, 1992),
it is clear that other immune compartments (lung capillary
beds, interstitial tissue and alveoli) could also play an
important role. Interestingly, the same relationship between
oestrous phases and LGL/NK cell number and activity was
found in the spleen by Rager et al. (1994) using the standard
splenic NK cytotoxicity assay and a different marker (5C6)
for identifying LGL/NK cells. Thus, the findings of the
present study in blood and those of Rager et al. (1994) in
splenocytes suggest that sex hormones or other oestrous
cycle-dependent hormonal factors induce a suppression of
cytotoxicity per LGL/NK cell during pro-oestrus/oestrus,
regardless of the specific location of these cells within the
body. Therefore, and because these phases of the oestrous
cycle were also characterised in experiment 1 by a higher
susceptibility to the LGL/NK-sensitive MADB106 tumour,
we hypothesise that decreased LGL/NK cell activity
contributes to the observed oestrous effects on tumour
metastasis.
The results of Experiment 3 also indicate that the number
of LGL/NK cells per ml of blood is lower in older females
(20 weeks old) than in younger females (10 weeks old) across
oestrous phases (Table I). We previously conducted a
longitudinal study and reported a similar decrease in
females, but not in males. In the male F344 rat, LGL/NK
number and activity continued to increase from 10 to 20
weeks of age (Page et al., 1995). This difference between the
sexes may be attributed, among other things, to differences in
chronic exposure to sex hormones and consequent differences
in levels of various interleukins. Indeed, chronic exposure to
oestradiol or progesterone under natural conditions (e.g.
pregnancy) (Gabrilovac et al., 1988) or artificial conditions
(e.g. some oral contraceptives, implants of oestradiol in
ovariectomised rodents) (Baker et al., 1989; Hanna and
Schneider, 1982; Seaman and Gindhart, 1979) was associated
with suppressed NK activity, as were chronically elevated
levels of prolactin (Hou and Zheng, 1988; Vidaller et al.,
1992). Other studies have suggested a biphasic effect of
oestrogens, with an early phase of increased NK activity and
a long-term/higher dose reduction in NK activity (Screpanti
et al., 1987). Thus, sex hormones may have both short-term
(e.g. oestrous/menstrual) and long-term effects on LGL/NK
number and activity.
Various mechanisms can mediate the effects of sex
hormones on LGL/NK cell activity. Although NK cells do
not appear to respond directly to sex hormones in vitro
(Callewaert et al., 1991), changes in levels of interleukins,
which are known to regulate LGL/NK cell activity, were
reported to occur during the oestrous cycle and in response
to sex hormones (Polan et al., 1994). The effects of sex
hormones can also be mediated via interaction with the stress
response. In mice, acute stress increased pituitary IL-1 a
content only during pro-oestrus (Nappi et al., 1994). Sex
hormones and the oestrous cycle have been reported to affect
baseline and stress levels of several stress hormones, including
glucocorticoids (CORT), and such stress hormones are
known to affect several immune functions, including NK
activity (Ader et al., 1991). Specifically, during pro-oestrus,
normal cycling rats manifest higher basal levels of CORT
(Raps et al., 1971) and a higher CORT response to stress
(Viau and Meaney, 1991). Administration of oestradiol was
shown to elevate basal and stress-induced levels of CORT in
ovariectomised rats (Viau and Meaney, 1991).
The findings of the current study may have implications
for the surgical management of breast cancer. Although a
topic of intense debate in the clinical literature, several
studies have indicated differential rates of cancer recurrence
(and different rates of long-term mortality) as a function of
the menstrual phase during which mastectomy is performed
(Badwe et al., 1991; Hrushesky et al., 1989; Saad et al., 1994;
Senie et al., 1991; Spratt et al., 1993). Our study in rats and
this clinical phenomenon have many characteristics in
common. Specifically, in our study cancer development was
found to be related to: (1) oestrous cyclicity; (2) the
metastatic process; (3) high oestradiol/low progesterone
levels; but (4) not related to a direct effect of sex hormones
on the tumour. Similarly, the description of the clinical
phenomenon provided by Badwe et al. (1991), Senie et al.
(1991) and Saad et al. (1994) indicated: (1) an association
between menstrual phase and the development of malig-
nancies; (2) the involvement of the metastatic process, which
is implicated by the reports that the clinical phenomenon
occurred only in woman bearing tumours with evident
metastatic potential (positive lymph nodes), and that
mortality was associated with cancer recurrence; (3) an
association of the high-risk period with increasing oestradiolOestrous effects on metastasis and NK activity
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levels and low progesterone levels; and (4) that the
relationship between menstrual phase during which surgery
is performed and subsequent metastasis occurred regardless
of whether or not the excised tumour expressed receptors for
sex hormones. These homologies between our findings and
the suggested phenomenon in women undergoing surgery
support the likelihood that this clinical phenomenon may
indeed occur under certain conditions. Further, our findings
suggest testable hypotheses as to the nature of the hormonal
and immunological mechanisms underlying the clinical
phenomenon and present an animal model that may be
used to expand our understanding of this phenomenon.
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